179 related articles for article (PubMed ID: 17510392)
1. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity.
Vikis H; Sato M; James M; Wang D; Wang Y; Wang M; Jia D; Liu Y; Bailey-Wilson JE; Amos CI; Pinney SM; Petersen GM; de Andrade M; Yang P; Wiest JS; Fain PR; Schwartz AG; Gazdar A; Gaba C; Rothschild H; Mandal D; Kupert E; Seminara D; Viswanathan A; Govindan R; Minna J; Anderson MW; You M
Cancer Res; 2007 May; 67(10):4665-70. PubMed ID: 17510392
[TBL] [Abstract][Full Text] [Related]
2. V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.
Matsushima S; Ohtsuka K; Ohnishi H; Fujiwara M; Nakamura H; Morii T; Kishino T; Goto H; Watanabe T
J Thorac Oncol; 2014 Sep; 9(9):1377-84. PubMed ID: 25057940
[TBL] [Abstract][Full Text] [Related]
3. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
4. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients.
Hashida S; Soh J; Toyooka S; Tanaka T; Furukawa M; Shien K; Yamamoto H; Asano H; Tsukuda K; Hagiwara K; Miyoshi S
Oncol Rep; 2014 Jul; 32(1):145-52. PubMed ID: 24842519
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
[TBL] [Abstract][Full Text] [Related]
6. Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma.
Centeno I; Blay P; Santamaría I; Astudillo A; Pitiot AS; Osorio FG; González-Arriaga P; Iglesias F; Menéndez P; Tardón A; Freije JM; Balbín M
BMC Cancer; 2011 May; 11():172. PubMed ID: 21575252
[TBL] [Abstract][Full Text] [Related]
7. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
[TBL] [Abstract][Full Text] [Related]
8. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
[TBL] [Abstract][Full Text] [Related]
9. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
Tseng JS; Su KY; Yang TY; Chen KC; Hsu KH; Chen HY; Tsai CR; Yu SL; Chang GC
Oncotarget; 2016 Jul; 7(30):48059-48069. PubMed ID: 27384480
[TBL] [Abstract][Full Text] [Related]
10. Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology.
Sakashita S; Shiba-Ishii A; Murata Y; Sekimoto R; Minami Y; Sato Y; Noguchi M
Pathol Res Pract; 2018 Aug; 214(8):1224-1230. PubMed ID: 29887244
[TBL] [Abstract][Full Text] [Related]
11. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
[TBL] [Abstract][Full Text] [Related]
12. EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.
Lu S; Yu Y; Li Z; Yu R; Wu X; Bao H; Ding Y; Shao YW; Jian H
J Thorac Oncol; 2019 Apr; 14(4):732-736. PubMed ID: 30610926
[TBL] [Abstract][Full Text] [Related]
13. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations.
Gazdar A; Robinson L; Oliver D; Xing C; Travis WD; Soh J; Toyooka S; Watumull L; Xie Y; Kernstine K; Schiller JH
J Thorac Oncol; 2014 Apr; 9(4):456-63. PubMed ID: 24736066
[TBL] [Abstract][Full Text] [Related]
14. EGFR-TKI-induced HSP70 degradation and BER suppression facilitate the occurrence of the EGFR T790 M resistant mutation in lung cancer cells.
Cao X; Zhou Y; Sun H; Xu M; Bi X; Zhao Z; Shen B; Wan F; Hong Z; Lan L; Luo L; Guo Z; Yin Z
Cancer Lett; 2018 Jun; 424():84-96. PubMed ID: 29524558
[TBL] [Abstract][Full Text] [Related]
15. Thoracoscopic rebiopsy to detect the T790M mutation after postoperative recurrence.
Hamaji M; Motoyama H; Menju T; Chen-Yoshikawa TF; Sonobe M; Kim YH; Date H
Interact Cardiovasc Thorac Surg; 2018 Oct; 27(4):606-608. PubMed ID: 29618075
[TBL] [Abstract][Full Text] [Related]
16. EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts.
Lavdovskaia ED; Iyevleva AG; Sokolenko AP; Mitiushkina NV; Preobrazhenskaya EV; Tiurin VI; Ivantsov AO; Bizin IV; Stelmakh LV; Moiseyenko FV; Karaseva NA; Orlov SV; Moiseyenko VM; Korzhenevskaya MA; Zaitsev IA; Kozak AR; Chistyakov IV; Akopov AL; Volkov NM; Togo AV; Imyanitov EN
Oncol Res Treat; 2018; 41(10):634-642. PubMed ID: 30145586
[TBL] [Abstract][Full Text] [Related]
17. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
Suda K; Murakami I; Sakai K; Tomizawa K; Mizuuchi H; Sato K; Nishio K; Mitsudomi T
Lung Cancer; 2016 Jan; 91():36-40. PubMed ID: 26711932
[TBL] [Abstract][Full Text] [Related]
19. Detection of low-level EGFR T790M mutation in lung cancer tissues.
Oh JE; An CH; Yoo NJ; Lee SH
APMIS; 2011 Jul; 119(7):403-11. PubMed ID: 21635547
[TBL] [Abstract][Full Text] [Related]
20. Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.
Jukna A; Montanari G; Mengoli MC; Cavazza A; Covi M; Barbieri F; Bertolini F; Rossi G
J Thorac Oncol; 2016 Apr; 11(4):e49-51. PubMed ID: 26746366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
